Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Eyes U.S. Expansion With Major Sales Force Boost

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo plans to more than double its U.S. sales force by 2010 in an effort to further expand outside of its home Japanese market, the firm announced Feb. 14

You may also be interested in...



Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication

If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.

Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA

Combination of olmesartan and amlodipine can be used alone or in conjunction with other antihypertensives, firm says.

Daiichi Sankyo Will Focus On Six Therapeutic Areas

Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel